Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | 23,623 | 24,203 |
| Sales and marketing | 26,346 | 23,047 |
| General and administrative | 20,984 | 17,399 |
| Amortization of intangible assets | 419 | 419 |
| Total operating expenses | 90,080 | 82,047 |
| Loss from operations | (19,206) | (29,604) |
| Interest and other income, net | 2,080 | 2,679 |
| Interest expense | (2,889) | (2,905) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's D&A?
- Adaptive Biotechnologies (ADPT) reported D&A of $419K in Q1 2026.
- How has Adaptive Biotechnologies's D&A changed year-over-year?
- Adaptive Biotechnologies's D&A decreased by 0.0% year-over-year, from $419K to $419K.
- What is the long-term trend for Adaptive Biotechnologies's D&A?
- Over 4 years (2021 to 2025), Adaptive Biotechnologies's D&A has grown at a 0.0% compound annual growth rate (CAGR), from $1.7M to $1.7M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Adaptive Biotechnologies's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude